D
Draslovka
Specializing in chemical solutions for ion exchange resins, polymerization, and pharmaceutical intermediates
About Draslovka
Draslovka is a chemical company that focuses on producing specialized chemical solutions for various industries. The company operates in the chemical industry, providing products such as ion exchange resins, polymerization agents, and pharmaceutical intermediates. Draslovka serves clients in the agricultural, pharmaceutical, and biotechnological sectors. The company’s business model revolves around manufacturing and supplying high-quality chemical compounds that are essential for various industrial processes. Draslovka generates revenue by selling these specialized chemicals to businesses that require them for their production processes. The company is known for its expertise in producing chelating agents, free carboxylic acids, and peptide synthesis intermediates, which are crucial for the development of insecticides, pesticides, and pharmaceuticals. Draslovka's products are also used in modern peptide synthesis, which is essential for creating new peptide compounds efficiently. The company’s market includes both domestic and international clients who rely on its chemical solutions for their manufacturing needs.
Source: Dealroom company dataAt a glance
- Founded
- 1906
- Headquarters
- Prague, Czechia
- Sector
- Chemicals
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Oaktree Capital Management
JP Morgan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Draslovka on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Draslovka on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.